Drug Approval | December 21, 2024
USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck has also decided to end the favezelimab clinical development program
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Aims to become India’s leading cancer testing company
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Venus Remedies secures marketing authorization in Philippines
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
The celebrations began with the unveiling of the Biocon Anthem
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Subscribe To Our Newsletter & Stay Updated
